Show simple item record

dc.contributor.authorMyers, R.M.
dc.contributor.authorHill, B.T.
dc.contributor.authorShaw, B.E.
dc.date.accessioned2019-06-21T18:46:33Z
dc.date.available2019-06-21T18:46:33Z
dc.date.issued2018
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85033592450&doi=10.1002%2fcncr.31114&partnerID=40&md5=ba9a5449b294d0064b824a72d771fc54
dc.identifier.urihttp://hdl.handle.net/10713/9772
dc.description.abstractBACKGROUND: Autologous hematopoietic cell transplantation (auto-HCT) is a standard therapy for relapsed classic Hodgkin lymphoma (cHL) and diffuse large B-cell lymphoma (DLBCL); however, long-term outcomes are not well described. METHODS: This study analyzed survival, nonrelapse mortality, late effects, and subsequent malignant neoplasms (SMNs) in 1617 patients who survived progression-free for ?2 years after auto-HCT for cHL or DLBCL between 1990 and 2008. The median age at auto-HCT was 40 years; the median follow-up was 10.6 years. RESULTS: The 5-year overall survival rate was 90% (95% confidence interval [CI], 87%-92%) for patients with cHL and 89% (95% CI, 87%-91%) for patients with DLBCL. The risk of late mortality in comparison with the general population was 9.6-fold higher for patients with cHL (standardized mortality ratio [SMR], 9.6) and 3.4-fold higher for patients with DLBCL (SMR, 3.4). Relapse accounted for 44% of late deaths. At least 1 late effect was reported for 9% of the patients. A total of 105 SMNs were confirmed: 44 in the cHL group and 61 in the DLBCL group. According to a multivariate analysis, older age, male sex, a Karnofsky score < 90, total body irradiation (TBI) exposure, and a higher number of lines of chemotherapy before auto-HCT were risk factors for overall mortality in cHL. Risk factors in DLBCL were older age and TBI exposure. A subanalysis of 798 adolescent and young adult patients mirrored the outcomes of the overall study population. CONCLUSIONS: Despite generally favorable outcomes, 2-year survivors of auto-HCT for cHL or DLBCL have an excess late-mortality risk in comparison with the general population and experience an assortment of late complications. Cancer 2018;124:816-25. Copyright 2017 American Cancer Society. Copyright 2017 American Cancer Societyen_US
dc.description.urihttps://dx.doi.org/10.1002/cncr.31114en_US
dc.language.isoen-USen_US
dc.publisherJohn Wiley and Sons Inc.en_US
dc.relation.ispartofCancer
dc.subjectautologous hematopoietic cell transplanten_US
dc.subjectdiffuse large B-cell lymphomaen_US
dc.subjectHodgkin lymphomaen_US
dc.subjectlate effectsen_US
dc.subjectnonrelapse mortalityen_US
dc.subjectsurvivalen_US
dc.titleLong-term outcomes among 2-year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large b-cell lymphomaen_US
dc.typeArticleen_US
dc.identifier.doi10.1002/cncr.31114
dc.identifier.pmid29125192


This item appears in the following Collection(s)

Show simple item record